Skip to Content

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

How can we use tests to optimise ovarian cancer treatment with PARP-inhibitor? In this MEDtalk, Kristina Yvonne Kathe Lindemann, Associate Professor – Department of Gynaecological Oncology, Oslo University Hospital, gives her perspective on how we can secure which patients benefit from the treatment.

Kristina Lindemann

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top